AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32207659
Drug: Optimal pharmacologic
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacologic therapy (OPT)
Trial: 32207659
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy pacemakers (CRT-P)
Trial: 36456409
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication reconciliation (MC)
Trial: 33143640
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 ml/day)
Trial: 38018702
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no treatment
Trial: 34593990
Drug: AdVEGF-D gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdVEGF-D gene therapy (GT)
Trial: 35938348
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for insomnia (CBT‐I)
Trial: 36163030
Drug: Culturally tailored
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally tailored cognitive-behavioural intervention (5 sessions, 30-35 min each, weekly)
Trial: 33812334
Drug: Nab-paclitaxel/Gemcitabine (NAB-P/G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel/Gemcitabine (NAB-P/G)
Trial: 32843098
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexamethasone (16 mg/24 hours for 5 days followed by 8 mg/24 hours for 5 days) + standard ICU care
Trial: 32843098
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexamethasone + standard ICU care
Trial: 32583948
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (POLLUX)
Trial: 32583948
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with bortezomib and dexamethasone (CASTOR)
Trial: 33581737
Drug: Canagliflozin (CG)
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin (CG) 100 mg
Trial: 33983794
Drug: Sacubitril/valsartan 97/103mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 97/103mg twice daily
Trial: 33983794
Drug: Valsartan 160mg
RxNorm normalized name: VALSARTAN 160MG CAP
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160mg twice daily
Trial: 33415867
Drug: Acupoint thread-embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread-embedding therapy
Trial: 32207705
Drug: Complex biologically
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1 and SG2)
Trial: 32207705
Drug: Complex biologically
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1)
Trial: 34863038
Drug: LY2409021 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2409021 (100 mg)
Trial: 32135429
Drug: Buprenorphine and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine and naloxone treatment
Trial: 32881071
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) + Treatment as Usual (TAU) (n = 23)
Trial: 32881071
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) (n = 24)
Trial: 32615488
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g lyophilized juçara for 6 weeks
Trial: 33845035
Drug: 21 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 Gy intraoperative radiotherapy with electrons (ELIOT) in a single dose to the tumour bed during surgery
Trial: 36308305
Drug: Tablet app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet app-based program (n=26)
Trial: 32615994
Drug: Inhaled granulocyte-macrophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) for 6 months
Trial: 32959232
Drug: Younger male
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger male patients with pancreatic body and tail cancer, AJCC 8th N1 stage, without microvascular and peripancreatic fat invasion, CA 19-9 > 200 U/ml.
Trial: 32946355
Drug: Consolidation radiotherapy
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation radiotherapy (cRT) with a median dose of 30.6 Gy (range, 24-36 Gy)
Trial: 34743579
Drug: Erenumab (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (70 or 140 mg/month)
Trial: 34743579
Drug: Topiramate (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (50-100 mg/day)
Trial: 33951374
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine (5 µg of recombinant spike protein with 50 µg of Matrix-M1 adjuvant)
Trial: 37214968
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine
Trial: 33443609
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TT)
Trial: 33443609
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TT) combined with resistance training (TT + RT)
Trial: 33443609
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TT + RT)
Trial: 35977107
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium meal (CAL; 1000 mg)
Trial: 35977107
Drug: Isocaloric low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric low calcium meal (CON; <10 mg)
Trial: 33454584
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg
Trial: 33992274
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group (B)
Trial: 35580836
Drug: Abbreviated dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated dual antiplatelet therapy (DAPT)
Trial: 35580836
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy (DAPT)
Trial: 33076878
Drug: Biokesum® (Persicaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biokesum® (Persicaria minor extract), 250 mg/capsule, twice daily for 6 months
Trial: 34551124
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR HDM tablet (sublingual allergen immunotherapy)
Trial: 34280646
Drug: Conventional strains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strains (CONV; strains B and C: ADG0‐48 > 60 g/d)
Trial: 33805664
Drug: Psychoeducational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational group intervention (12 weekly sessions of 90 min)
Trial: 37342775
Drug: Non-CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-CPAP treatment
Trial: 35147680
Drug: AmBisome monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome monotherapy (40 mg/kg intravenous liposomal amphotericin B administered in 8 equal doses over 24 days)
Trial: 35147680
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (30 mg/kg intravenous AmBisome administered in 6 equal doses over 24 days + 1.4 g oral miltefosine administered in 2 daily doses of 50 mg over 14 days)
Trial: 33446902
Drug: 3-5 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-5 sessions of ALSS therapy
Trial: 33446902
Drug: 1-2 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 sessions of ALSS therapy
Trial: 33446902
Drug: ≥6 sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥6 sessions of ALSS therapy
Trial: 33446902
Drug: ≤2 sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≤2 sessions of ALSS therapy
Trial: 34059932
Drug: pirenzepine 75
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirenzepine 75 mg
Trial: 37750406
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg
Trial: 34059932
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg plus pirenzepine 75 mg
Trial: 34059932
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg alone (control)
Trial: 34043794
Drug: Dual hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual hormone clamp (cortisol and testosterone fixed)
Trial: 34704984
Drug: 2g amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g amoxicillin 1 hour prior to surgery
Trial: 33091856
Drug: Cinnamon Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon Patch (CP)
Trial: 34031921
Drug: All implants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implants (instrumented and non-instrumented)
Trial: 35689170
Drug: Regular conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular conventional medications
Trial: 32195950
Drug: Acyclovir and
RxNorm normalized name: Acyclovir and hydrocortisone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir and simulated PDT treatment (control)
Trial: 36456740
Drug: Positive pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive pressure therapy (PPT) combined with medications, duration of 8 months.
Trial: 36456740
Drug: Medications alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications alone (Control group), n=26.
Trial: 36456740
Drug: Positive pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive pressure therapy (PPT) combined with medications.
Trial: 36192552
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg volagidemab
Trial: 36192552
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg volagidemab
Trial: 36122501
Drug: Lentil-based meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentil-based meals (300 g)
Trial: 36122501
Drug: Lentil-based meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentil-based meals (600 g)
Trial: 36122501
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g lentils)
Trial: 36122501
Drug: Lentil-based meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentil-based meals (300 g and 600 g)
Trial: 35092891
Drug: TPTD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPTD 20 μg daily for an average of 6.1 weeks
Trial: 35092891
Drug: TPTD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPTD 20 μg daily
Trial: 33818442
Drug: ropivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine (40 mL/0.5%) + dexmedetomidine (1 μg/kg)
Trial: 33818442
Drug: ropivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine (40 mL/0.5%) + fentanyl (1 μg/kg)
Trial: 33818442
Drug: ropivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine (40 mL/0.5%) + verapamil (2.5 mg)
Trial: 33476571
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b (100 μg subcutaneously every 2 weeks) on top of phlebotomy and low-dose aspirin (100 mg daily)
Trial: 33476571
Drug: Phlebotomy (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy (300 mL per session to maintain haematocrit <45%) and low-dose aspirin (100 mg daily)
Trial: 35686634
Drug: Myo-inositol (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2000 mg) plus 400 μg folic acid daily from 14-24 gestational weeks
Trial: 35686634
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (400 μg of folic acid daily from 14-24 gestational weeks)
Trial: 33657259
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment (n = 31)
Trial: 33657259
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone acetate ointment (n = 32)
Trial: 35100429
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (NIC) 21 mg, daily
Trial: 35100429
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (PBO)
Trial: 33306247
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA treatment for <4 weeks in patients with F0-F3 liver fibrosis
Trial: 33306247
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA treatment for <8 weeks in patients with liver cirrhosis
Trial: 32975853
Drug: Acylated ghrelin
RxNorm normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acylated ghrelin infusion
Trial: 36461123
Drug: Expectation-optimised video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectation-optimised video with patients giving information about their mostly positive therapy outcomes (positive model)
Trial: 37468685
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec (IDeg)
Trial: 38064454
Drug: Optimal drug
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal drug therapy
Trial: 33252379
Drug: WHO-recommended second-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO-recommended second-line treatment (NRTI group)
Trial: 38677468
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (iNPWT)
Trial: 33271298
Drug: Hypocaloric high-protein
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric high-protein diet + fennel (2 capsule/day)
Trial: 33271298
Drug: Hypocaloric standardize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric standardize diet + fennel (2 capsule/day)
Trial: 32371987
Drug: TPN discontinuation
RxNorm normalized name: Entex HC Discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN discontinuation at 100 ml/kg/day
Trial: 32371987
Drug: TPN discontinuation
RxNorm normalized name: Entex HC Discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN discontinuation at 140 ml/kg/day
Trial: 34159620
Drug: Dexmedetomidine 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion (group DEX)
Trial: 34159620
Drug: Dexmedetomidine 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion combined with vatinoxan 130 µg kg−1 followed by 40 µg kg−1 h−1 infusion (group VAT)
Trial: 39213031
Drug: eGFR ≥90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≥90 mL/min/1.73 m²
Trial: 35234561
Drug: ROSE-010 100
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 100 µg
Trial: 35234561
Drug: ROSE-010 300
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 300 µg
Trial: 33475844
Drug: Near-infrared fluorescent
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Near-infrared fluorescent cholangiography (NIFC) with preoperative administration of indocyanine green (ICG)
Trial: 35508427
Drug: Mandala coloring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandala coloring for 30 min during premedication before chemotherapy
Trial: 32815423
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 7 or 14 mg
Trial: 33049709
Drug: Estradiol therapy
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol therapy
Trial: 33750239
Drug: Fear-associated human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fear-associated human chemosignals (three doses)
Trial: 33893329
Drug: Concurrent bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent bilateral stimulation of the ventrolateral PFC (regardless of polarity direction)
Trial: 32839029
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg/h for 30 min before the end of surgery) in groups DD (Dex), ID (Dex), and II(Dex)
Trial: 32622074
Drug: Ultrasonic scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaling (US) with usual oral hygiene instructions
Trial: 32622074
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with ultrasonic scaling (US)
Trial: 36451150
Drug: Intravenous esketamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esketamine, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Trial: 36451150
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Trial: 34169628
Drug: Carbon-assisted Q-switched
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon-assisted Q-switched Nd: YAG laser treatment
Trial: 32201062
Drug: L‐PRF membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF membrane
Trial: 33351452
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative 500 mg dose of methylprednisolone
Trial: 32180528
Drug: Coping with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping with depression program (individual psychoeducation based on the Neuman systems model, involving cognitive behavioral therapy techniques) administered at six sessions
Trial: 33725408
Drug: Low immunosuppression
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low immunosuppression (LI) with tacrolimus monotherapy
Trial: 33415860
Drug: Conventional Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Chinese and Western medicine (Control)
Trial: 33415860
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between treatment and control groups
Trial: 35169165
Drug: GLP-1/GIP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1/GIP combination
Trial: 34788325
Drug: Appropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate empirical antibiotic treatment
Trial: 35700592
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (120 mg/d)
Trial: 37553030
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg every 12 weeks
Trial: 35679030
Drug: Marine ω-3
RxNorm normalized name: marine collagen, soluble
DrugBank: Marine collagen, soluble (DB14246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine ω-3 fatty acids, 1 g per day
Trial: 33636278
Drug: Enzalutamide monotherapy
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide monotherapy with external beam radiation therapy (RT) for 6 months